EU Says Does Not Want Trade War with Beijing

Vendors offer desserts to pedestrians at a store in Beijing, China, 09 November, 2024. EPA/ANDRES MARTINEZ CASARES
Vendors offer desserts to pedestrians at a store in Beijing, China, 09 November, 2024. EPA/ANDRES MARTINEZ CASARES
TT

EU Says Does Not Want Trade War with Beijing

Vendors offer desserts to pedestrians at a store in Beijing, China, 09 November, 2024. EPA/ANDRES MARTINEZ CASARES
Vendors offer desserts to pedestrians at a store in Beijing, China, 09 November, 2024. EPA/ANDRES MARTINEZ CASARES

The EU does not want a trade war with Beijing but five years of talks have yielded no real progress, the bloc's ambassador to China said on Saturday, adding that concern was growing over Chinese market access for European medical devices.
Trade frictions between the bloc and China have intensified over the past year after the EU launched an investigation into Chinese-made imports of electric vehicles (EVs) that prompted Beijing to launch probes into Europe's pork and dairy industries and curb brandy imports.
New EU tariffs of up to 45.3% on Chinese EV imports came into effect last week.
On top of that, the EU launched a probe into China's public procurement of medical devices in April, which Beijing swiftly criticized at the time.
Speaking at an event in Shanghai, the EU's Ambassador to China Jorge Toledo said talks with European medical device makers had shown they were being discriminated against in Chinese public procurement.
"We have found out, that it's clear ... European companies, that have been producing medical devices in China for the last two decades, are being discriminated against their Chinese competitors in public procurement," Toledo said at the 30th anniversary celebration of the China Europe International Business School.
"If that is true, and we know it's true, we will treat Chinese companies in Europe the same way we are treated here," Reuters quoted him as saying. "We don't want a trade war. We just want transparency. We want a level playing field."



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.